These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 2827081)

  • 1. Relationship of serum CA125 and lipid-associated sialic acid tumor-associated antigen levels to the disease status of patients with gynecologic malignancies.
    Stratton JA; Rettenmaier MA; Phillips HB; Herabutya S; DiSaia PJ
    Obstet Gynecol; 1988 Jan; 71(1):20-6. PubMed ID: 2827081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The clinical significance of CA125 in patients with gynecological tumors--a comparative study on CA125 and other tumor markers].
    Suzumori K; Yasui Y; Asai H; Hisaoka T; Mizuno K; Yagami Y
    Gan No Rinsho; 1985 May; 31(5):544-8. PubMed ID: 3860666
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Analysis of CA 125 assay system and its diagnostic significance in gynecologic tumors].
    Shimizu Y; Akagaki E; Hirota K; Kono M; Miura S; Okudaira Y
    Nihon Sanka Fujinka Gakkai Zasshi; 1985 Dec; 37(12):2813-20. PubMed ID: 3866801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical evaluation of specificity of serum CA125 as a tumor marker of ovarian carcinoma].
    Iwasaka T; Ohkuma Y; Yoshimura T; Sugimori H
    Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jun; 38(6):917-23. PubMed ID: 2426378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CA125 antigen levels in obstetric and gynecologic patients.
    Niloff JM; Knapp RC; Schaetzl E; Reynolds C; Bast RC
    Obstet Gynecol; 1984 Nov; 64(5):703-7. PubMed ID: 6208522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Relationship between serum levels and immunohistological tissue levels of CA 125 and CEA in epithelial ovarian cancers: its implications for tumor cell type specificity].
    Oishi T; Maruo T; Iwasaki M; Mochizuki M
    Nihon Sanka Fujinka Gakkai Zasshi; 1986 Sep; 38(9):1595-604. PubMed ID: 3464659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical evaluation of a cancer antigen CA125 associated with ovarian cancer. (III) Serum CA125 levels in patients with ovarian cancer and other gynecological tumors].
    Suzuki M; Sekiguchi I; Tamada T; Sakurabayashi I; Kawai T
    Rinsho Byori; 1985 Feb; 33(2):173-7. PubMed ID: 3858562
    [No Abstract]   [Full Text] [Related]  

  • 8. Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer.
    Einhorn N; Bast RC; Knapp RC; Tjernberg B; Zurawski VR
    Obstet Gynecol; 1986 Mar; 67(3):414-6. PubMed ID: 2418395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Ca 125 as tumor marker in ovarian carcinoma.
    Krebs HB; Goplerud DR; Kilpatrick SJ; Myers MB; Hunt A
    Obstet Gynecol; 1986 Apr; 67(4):473-7. PubMed ID: 3008052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-associated antigen Ca 125 before and during the treatment of ovarian carcinoma.
    Kivinen S; Kuoppala T; Leppilampi M; Vuori J; Kauppila A
    Obstet Gynecol; 1986 Apr; 67(4):468-72. PubMed ID: 3008051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Relationship between serum CA125 level and second-look findings in ovarian cancers].
    Liu LY
    Zhonghua Zhong Liu Za Zhi; 1992 Jul; 14(4):287-9. PubMed ID: 1327702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A study of localizations and serum data; four tumor markers (CA125, CA19-9, CEA and TPA) in ovarian cancers].
    Kataoka A; Yakushiji M
    Nihon Gan Chiryo Gakkai Shi; 1990 Jan; 25(1):47-54. PubMed ID: 2157782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical value of a new serum tumor marker CA602 in ovarian cancers].
    Suzuki M; Sekiguchi I; Ohwada M; Aida I; Tamada T
    Nihon Gan Chiryo Gakkai Shi; 1990 Jul; 25(7):1454-60. PubMed ID: 2170549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Diagnostic usefulness of stepwise discriminant analysis employing the values of CA125, TPA, IAP, CEA and ferritin in sera measured simultaneously for gynecological malignant neoplasms].
    Yabushita H; Masuda T; Hattori A; Noguchi M; Ito Y; Nakanishi M; Ishihara M
    Nihon Sanka Fujinka Gakkai Zasshi; 1985 Sep; 37(9):1883-92. PubMed ID: 2997349
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The sensitivity of the CA125 immunoradiometric assay for patients with epithelial ovarian cancer and its correlation with complex treatment].
    Shi W; Zhang YJ; Jiang CY
    Zhonghua Fu Chan Ke Za Zhi; 1994 Oct; 29(10):604-6, 637-8. PubMed ID: 7712875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
    Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
    Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum and tissue measurements of CA72-4 in ovarian cancer patients.
    Negishi Y; Iwabuchi H; Sakunaga H; Sakamoto M; Okabe K; Sato H; Asano G
    Gynecol Oncol; 1993 Feb; 48(2):148-54. PubMed ID: 8381375
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical evaluation of the tumor marker CA125 in ovarian tumor (a cooperative study among 8 institutions)].
    Kato T; Nishimura H; Hamai J; Yamabe T; Nakajima H; Nakano T; Noda K; Teshima K; Suzuki H; Ueda G
    Nihon Gan Chiryo Gakkai Shi; 1985 Dec; 20(10):2338-45. PubMed ID: 3007640
    [No Abstract]   [Full Text] [Related]  

  • 19. [The clinical usefulness of serum CA72-4 analysis in patients with ovarian cancer].
    Kobayashi H
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 May; 41(5):585-9. PubMed ID: 2754289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of CA 125 and conventional examinations in diagnosing progressive carcinoma of the ovary.
    van der Burg ME; Lammes FB; Verweij J
    Surg Gynecol Obstet; 1993 Apr; 176(4):310-4. PubMed ID: 8460404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.